Ceretas (ASX:CTS)
ASX announcement history & article coverage
Transparent by design.
Announcments by Ceretas (ASX:CTS) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Ethics Committee Approval Secured for Additional Trial Sites
Ceretas secures ethics approval for additional CERE-CALM trial sites to advance Phase 2 Alzheimer's study
Appendix 4G
Corporate Governance Statement
Appendix 4E & Annual Report 30 June 2026
Ceretas Limited reports FY26 loss of $1.63 million on $1.28 million revenue, completes $8 million IPO to fund Alzheimer's-focused ultrasound device development
Change of Address
Investor Presentation
Initial Director's Interest Notice x 5
Ceretas Lists on ASX
Becoming a substantial holder
Becoming a substantial holder
Becoming a substantial holder
Pre-Quotation Disclosure
Securities Trading Policy
Corporate Governance Statement
Employee Securities Incentive Plan
Half-Year Report 31 December 2025
Annual Report 2025
Ceretas Limited reports first period loss, secures $2.39M grant and prepares for ASX listing
Constitution
Replacement Prospectus
Ceretas Limited launches $8 million IPO to fund clinical trials and development of therapeutic ultrasound device for Alzheimer's treatment
Appendix 1A and Information Form and Checklist
ASX Market Announcement - Admission and Quotation